Abstract
Introduction
Hepatitis A and hepatitis E share several characteristics that set them apart from the other three recognized types of viral hepatitis (hepatitis B, C, and D) that afflict humans. The former types are acute, self-limiting diseases that are spread by nonenveloped viruses, principally via the fecal-oral route; whereas the latter frequently progress to chronicity and are transmitted by enveloped viruses, principally via blood.
Numerous seroepidemiological studies have revealed that, at least until quite recently, virtually everyone in developing countries of Africa, Asia, and South America has been infected with the virus that causes hepatitis A (hepatitis A virus) by the age of 5 yr and that 10 to 80% of such populations have been infected with the virus that causes hepatitis E (hepatitis E virus). Thus, because the vast majority of the world's population live in these countries, up to five billion of the world's six billion population have been infected with hepatitis A virus, and up to two billion have been infected with hepatitis E virus. In the United States, hepatitis A currently accounts for almost half of the cases of acute clinical hepatitis; in contrast, hepatitis E accounts for virtually none of the cases.
Hepatitis A virus (HAV 1 ) is classified in its own genus, Hepatovirus, in the Picornaviridae family of viruses (Minor et al. 1995) . Thus, it is a relative of other pathogens of humans (polioviruses and other enteroviruses and rhinoviruses) and animals (foot-and-mouth disease virus and the closest relative to HAV, avian encephalomyelitis virus) (Marvil et al. 1999) . HAV is a small virus with an RNA genome. It is very stable to physical agents and can persist in the environment, including in food and water. It is taken up and concentrated by shellfish, and contaminated raw or undercooked shellfish is a recognized vehicle for transmission of the virus. However, the principal mode of transmission is person-to-person via occult contamination with feces.
Hepatitis A is believed by some to be an ancient disease. Outbreaks of hepatitis were reported during military campaigns of the 17th through early 20th centuries, when the disease came to be known as "campaign jaundice" (Zuckerman 1976) . Outbreaks of hepatitis were also common among civilians, and in 1912, Cockayne designated such epidemics of jaundice "infective hepatitis" (Cockayne 1912) . By the 1940s, a second form of hepatitis ("serum hepatitis") was recognized, and in 1947, MacCallum introduced the terms "hepatitis A" for infectious hepatitis and "hepatitis B" for serum hepatitis (MacCallum 1947) . Volunteer studies in adults and children in the 1950s, 1960s, and 1970s demonstrated the fecal-oral route of transmission of hepatitis A and the blood-borne transmission of hepatitis B (Zuckerman 1976) . In 1973, HAV was first visualized by electron microscopy, and in 1979, the virus was first recovered and serially passaged in cell culture (Feinstone et al. 1973; Provost and Hilleman 1979) . Recovery in cell culture was difficult, requiring many weeks to adapt the virus to in vitro cultivation. HAV remains the only human hepatitis virus that replicates reproducibly in cell culture.
Hepatitis E virus (HEV 1 ) was once considered a calicivirus but is currently unclassified. HEV is a small virus with an RNA genome and initial analysis revealed a genomic organization similar to that of the caliciviruses. However, the ordering of the viral genes, codon usage, and sequence analysis all indicate that HEV had origins that were different from the Caliciviridae, and it was recently declassified (Pringle 1998) . By sequence analysis, its closest relatives are rubella virus, currently classified as a togavirus, and beet necrotic yellow vein virus, a plant furovirus. The principal mode of spread of HEV is via water contaminated with feces. Person-to-person spread of HEV is uncommon, perhaps because the titer of this virus in feces is less than that of HAV. HEV has also been reported to be less stable in the environment than HAV, but this report is unconfirmed.
The recorded history of hepatitis E dates only to 1980, when the development of sensitive tests for anti-HAV permitted a serological analysis of epidemics of water-borne hepatitis that had previously been classified as hepatitis A. However, these epidemics, which occurred in regions where HAV infection was known to occur in virtually all infants and young children, occurred principally in young adults, a population that should have been solidly immune to clinical hepatitis A. Serological testing revealed that, as suspected, all of the hepatitis patients tested had pre-existing immunoglobulin G (IgG 1 ) anti-HAV and none had immunoglobulin M (IgM   1   ) anti-HAV, which would have indicated recent infection (Khuroo 1980; Wong et al. 1980) . Thus, serological evidence pointed to a previously unrecognized cause of water-borne viral hepatitis. The disease was initially called "epidemic non-A, non-B hepatitis" or "enterically transmitted non-A, non-B hepatitis" (ENANB 1 ). In 1983, Balayan experimentally transmitted ENANB to a human volunteer, and the virus was visualized by immune electron microscopy in the volunteer's feces ). Balayan (who was the volunteer) also successfully transmitted HEV to cynomolgus (Macaca fascicularis) monkeys ). In 1990, Reyes et al. succeeded in cloning and sequencing a part of the genome of the virus, and it was renamed hepatitis E virus (Reyes et al. 1990) .
Ironically, hepatitis occurring in previous centuries and the early 20th century and known variously as "campaign jaundice" and "infective hepatitis" was probably not hepatitis A but instead, hepatitis E, because the epidemiological descriptions of such disease resemble those of hepatitis E, not hepatitis A .
Animal Models of Hepatitis A

Historical Perspective: Nonhuman Primates
Despite numerous attempts to transmit hepatitis A to a variety of common and uncommon laboratory animals (Paul 1954) , successful transmission has been achieved only in human and nonhuman primates. Even among nonhuman primates, the host range is quite limited. Identifying and characterizing the best species for studying hepatitis A has been laborious, expensive, frustrating, and, in some instances, unpredictable.
Tamarins
For many years, the twin impediments of the inability to isolate HAV in cell culture and the inability to transmit it to a laboratory animal served to restrict progress in the control of hepatitis A. Among the first reports of infection of nonhuman primates was the report of transmission of hepatitis to white-lipped tamarins (Saguinus nigricollis and Saguinus fuscicollis) and cotton-topped tamarins (Saguinus oedipus) in 1967 (Deinhardt et al. 1967) . Small groups of animals were inoculated with serum from patients thought to have hepatitis A, based on clinical and epidemiological criteria. Two of five attempts appeared at least partially successful and the disease was serially transmissible to other tamarins. The transmissible agent from one serum sample, obtained from a young surgeon (G.B., hereafter referred to as GB 1 ) who had developed acute hepatitis without known exposure, was chosen for additional study. Subsequently, only one of other attempts to confirm these studies resulted in the isolation of what appeared to be a similar virus from normal uninoculated tamarins . Parks and Melnick suggested that the transmissible agent described by Deinhardt was, in fact, a tamarin virus. They also provided evidence that the virus might have physical characteristics that were distinct from those of hepatitis A virus . Subsequent studies of the biophysical and serological properties of the GB agent confirmed that it was not related to hepatitis A virus (Deinhardt et al. 1975; Holmes et al. 1973; Karayiannisetal. 1989; Purcell et al. 1975 ). However, it was not until 1995 that the mystery of the GB agent was solved. Scientists at Abbott Laboratories resurrected the GB agent from stored frozen specimens of the original transmission series in tamarins, and using sophisticated molecular techniques (representational difference analysis), they identified not one but two transmissible agents in the serum of tamarins infected with the GB agent (Schlauder et al. 1995) . The first of these they called "GB virus-A" and the second "GB virus-B." Both belong to the Flaviviridae family of viruses. It is probable that both GB viruses A and B are tamarin viruses that were picked up in the earliest passages by Deinhardt's group.
Deinhardt's group subsequently transmitted hepatitis A to tamarins with carefully selected serum samples obtained from human volunteers and supplied under code (Holmes et al. 1969 (Holmes et al. , 1971 . The susceptibility of tamarins for hepatitis A was confirmed by various laboratories (Lorenz et al. 1970; Mascoli et al. 1973; Maynard et al. 1975b ) using a different species of tamarin, Saguinus mystax, a species first suggested for hepatitis studies by Hillis (Hillis 1968 ). Provost later reported that another species of tamarin, 5. "rufiventer" (probably the same as S. labiatus) was susceptible to infection with HAV; S. mystax and 5. labiatus were shown to be more sensitive for studies of hepatitis A than S. nigricollis, S. fuscicollis, or S. oedipus (Provost et al. 1977) .
Chimpanzees
Numerous attempts to transmit hepatitis A to chimpanzees were reported by the mid-1970s, but most of these yielded negative or equivocal results. However, Deinhardt reported evidence for hepatitis in two thirds of 37 chimpanzees that were wild-caught in the Belgian Congo and immediately inoculated with clinical materials (Deinhardt et al. 1962) . Unfortunately, the results could not be regularly reproduced, probably because of inability to screen animals for prior exposure to hepatitis viruses.
Epidemiological evidence for susceptibility of chimpanzees came from studies of animal handlers who developed hepatitis after handling newly caught chimpanzees (Zuckerman 1976) . The development of sensitive serological tests for antibody to HAV (anti-HAV 1 ) provided a means of screening captive chimpanzees as well as other primates for evidence of prior exposure to HAV. Screening of jungle-caught chimpanzees and colony-born animals revealed that most of the former had antibody to hepatitis A virus whereas the latter were seronegative (Kessler et al. 1982; Purcell and Dienstag 1978) . Attempts to infect seronegative chimpanzees with HAV were successful, thus providing evidence that the previous failures to infect chimpanzees probably were the result of attempting to infect immune animals Maynard et al. 1975a) .
Other Species
Hepatitis A-like disease had also been reported in animal handlers who had come in contact with woolly monkeys, and two woolly monkeys were shown to have been infected with HAV after exposure to an apparently infectious chimpanzee in a zoo (CDC 1971; Dienstag et al. 1976 ). However, attempts to transmit HAV to woolly monkeys were less successful than attempts to infect tamarins and chimpanzees (Purcell and Dienstag 1978) .
Naturally Occurring Infections
The development of serological tests for HAV and anti-HAV both refined the search for suitable animal models of hepatitis A and provided reagents for more sensitive and specific assays. Immune electron microscopy was the first assay for anti-HAV to be developed (Feinstone et al. 1973) . It utilized, as a source of antigen, HAV-rich feces obtained during the acute phase of hepatitis A in humans. Immune electron microscopy was used to confirm the successful transmission of HAV to S. mystax tamarins and to chimpanzees and the serological differentiation of the GB agent from hepatitis A . At approximately the same time, Miller utilized HAV obtained from the livers of acutely infected S. mystax tamarins as a source of antigen for the development of a less cumbersome and very sensitive immune adherence hemagglutination assay, which could be used for testing large numbers of sera for anti-HAV (Miller et al. 1975) . Rapidly thereafter, other sensitive assays, including radioimmunoassay and enzyme-linked immunosorbent assay, were developed and used to define the seroepidemiology of HAV. Interestingly, numerous species of nonhuman primates (but not other species of animals) were found to have naturally acquired anti-HAV (Table 1) . In some cases, exposure to HAV could be traced to apparent exposure within primate facilities, but in other cases newly caught animals were already anti-HAV positive. Species of nonhuman primates with high prevalences of anti-HAV included chimpanzees, vervets, patas monkeys, several species of macaques (rhesus, cynomolgus, pig-tailed, and stump-tailed), and owl monkeys. Species with intermediate prevalences of anti-HAV included grivets, baboons, spider monkeys, and cebus monkeys. Species that had low prevalences of antibody, that were seronegative, or for which only small numbers of animals were available for testing are also listed in Table 1 .
In several instances, a very large difference in anti-HAV prevalence existed between wild-caught and colony-reared animals of the same species. Wild-caught chimpanzees had a much higher prevalence of anti-HAV than domestically raised animals ( Table 1 ). In contrast, wild-caught cynomolgus macaques and owl monkeys had little or no anti-HAV upon capture, but virtually all animals that had been in captivity for a few months had anti-HAV (Table 1) . In a separate facility, just the opposite was observed: More than half of owl monkeys obtained from outside sources (other facilities) had antibody to HAV whereas in-house raised animals were virtually devoid of such antibody (Lemon etal. 1982 ). These observations point to the importance of rigorous infection control in animal husbandry for controlling diseases in primate facilities.
Serological evidence of natural transmission of HAV to nonhuman primates in captivity has been confirmed by prospective studies of newly captured animals (Table 2) . Thus, epidemic and endemic infection of newly caught rhesus monkeys, cynomolgus macaques, African green monkeys, and owl monkeys has been documented, in most cases by clinical, virological, and serological examination.
Host Range
Unfortunately, antibody prevalence studies and prospective studies of HAV infection among nonhuman primates have not necessarily been predictive of suitability of specific animal species as animal models for hepatitis A. Instead, transmission studies, which are summarized in Table 3 , have delineated suitable species. Thus, seronegative chimpanzees were readily infected with HAV and developed all of the biochemical and histological markers of viral hepatitis. Similarly, certain species of tamarins were highly susceptible to infection with HAV and developed hepatitis whereas other closely related species were relatively or completely refractory to infection ( Table 4 ).
Species that developed anti-HAV after exposure to HAV but did not develop evidence of hepatitis were rhesus 5,10 5, 10,11 1,4,7,10,14 1,7,10,12,14 7,10 10 1,4,7,10,14 14 10 7,10,14 7,9,10,11,12,13,14 9 ,11 Modified from Balayan 1992. Wild: bled shortly after capture. Colony-born: offspring from breeding facility. Captive: source not specified. SPF: specific pathogen free or otherwise isolated colony. 1. Balayan, 1992; 2. Baptista et al., 1993; 3. Burke et al., 1981; 4. Eichberg and Kalter, 1980; 5. Kessler et al., 1982; 6. Lemon et al., 1982; 7. Miller et al., 1975; 8. Provost et al., 1977; 9. Purcell, unpublished data; 10. Purcell and Dienstag, 1978; 11. Purcell and Emerson, unpublished data; 12. Savinskaya et al., 1983; 13. Slighter et al., 1988; 14. Smith et al., 1980. macaques, cebus monkeys, a vervet, and an owl monkey (Purcell and Dienstag 1978;  Table 3 ). All of these nonhuman primates were inoculated with the same pool of human HAV. In other studies with different inocula, rhesus macaques, cynomolgus macaques, vervets, owl monkeys, and one species of bush baby developed hepatitis after inoculation with strains of HAV that had been recovered from either spontaneously infected nonhuman primates or human cases of hepatitis A.
The reason for these discrepancies among challenge experiments and between challenge experiments and seroepidemiological studies is not entirely clear; however, certain strains of HAV that are readily transmitted to nonhuman primates have been shown to be unique viruses, probably of simian origin. Three of these strains are now classified as simian strains of HAV; they were recovered from spontaneous infections of cynomolgus monkeys (two) and a vervet (one), respectively (Robertson et al. 1992) . HAV strains have also been recovered from spontaneously infected rhesus macaques, but these have not been genetically characterized (Lankas and Jensen 1987; Shevtsova et al. 1988) . A fourth genetic variant of HAV was recovered from spontaneous infections of owl monkeys with hepatitis A (Brown et al. 1989 ). The genetic variant was originally believed to be a 9,10,13,16,18, 19,22,24,31 24,29 Modified from Balayan 1992 and Vitral et al., 1998 . Some scores represent ranges of discrepant results from different laboratories. 0: not susceptible. 4+: highly susceptible.
1. Andzhaparidze et al., 1987; 2. Asher et al., 1995; 3. Balayan 1992; 4. Brown et al., 1989; 5. Cohen et al., 1989; 6. Dienstag et al., 1975; 7. Doroshenko et al., 1990; 8. Emerson et al., 1996; 9. Holmes et al., 1971; 10. Karayiannis et al., 1986; 11. Keenan et al., 1984; 12. Korzaya et al., 1991; 13. Krawczynski et al., 1981; 14. Lapin and Shevtsova 1990; 15. LeDuc et al., 1983; 16. Lorenz et al., 1970; 17. Mao et al., 1981; 18. Mascoli et al., 1973; 19. Mathiesen et al., 1980; 20. Maynard et al., 1975a; 21. Nainan et al., 1991; 22. Poleshchuk et al., 1990; 23. Prevot et al., 1992; 24. Provost et al., 1977; 25. Purcell and Dienstag, 1978; 26. Shevtsova et al., 1990; 27. Shevtsova et al., 1988; 28. Trahan et al., 1987; 29. Vitral etal., 1995; 31. Yamanouchi, 1985; 32. Zamyatinaetal., 1990 . *Results reported as similar to those for C. jacchus but data not given 1. Holmes etal., 1971; 2. Mascolietal., 1973; 3. Provost etal.,1977. simian virus, but other related strains were subsequently recovered from human cases of hepatitis A in several countries (Robertson et al. 1992) . Nevertheless, the virus appears to be particularly well adapted to replication in owl monkeys, possibly because it had been endemic in a primate colony for an undetermined period of time (Lemon et al. 1982) . One simian strain, recovered from a spontaneously infected vervet in Russia, produced hepatitis when inoculated into vervets, rhesus monkeys, and 5. mystax tamarins, but it was attenuated for chimpanzees and caused only a seroconversion in the absence of hepatitis (Emerson et al. 1996) . However, chimpanzees and tamarins that had been infected with the simian strain of HAV were protected against hepatitis when challenged with virulent human HAV. Thus, at least one simian strain of HAV was biologically different from many human strains of HAV, which regularly produce hepatitis in chimpanzees and certain species of tamarins but only irregularly produce hepatitis in other Old World and New World monkeys (Sjogren and Siegl 1997) . Epidemics of HAV infection among captive macaques and owl monkeys can best be explained by infections with simian strains of HAV or human strains that have been adapted to replication in these monkey species by endemic transmission over time. Similarly, serial passage of human HAV strains in nonhuman primates can result in adaptation of those strains to better replication of the virus in the new host. Simian HAV/Old World monkey models are useful for studying the biology of HAV infection because these monkeys are more readily available than tamarins or chimpanzees.
Course of HAV Infection in Animal Models
Two animal species, chimpanzees and 5. mystax tamarins, have been the most widely used species for the propagation and study of HAV, and they have yielded the greatest amount of information. A third species, the owl monkey, has also proven to be a useful animal model. Based on data obtained principally from these three species, a picture of the pathogenesis and natural history of hepatitis A in nonhuman primates has emerged ( Figure 1 ). Exposure to HAV usually occurs via the oral route. However, the virus can be transmitted parenterally, and hepatitis A has been reported occasionally after exposure to blood or blood products. Ironically, HAV is more readily transmitted to nonhuman primates by intravenous inoculation compared with oral inoculation: Oral administration of HAV to chimpanzees and S. mystax tamarins has been shown to be 32,000-fold less efficient than intravenous inoculation (Sjogren and Siegl 1997) .
After exposure, the first evidence of infection is detection of the virus in the liver. Soon thereafter, it can be detected in the blood, bile, and feces. Although a site of replication in the intestinal tract has been sought by many researchers, it has never unequivocally been found; current thinking is that viruses found in saliva, the pharynx, and the intestinal tract reach the site via replication in hepatocytes and excretion into the blood and into the bile (Asher et al. 1995; Cohen et al. 1989; Karayiannis et al. 1986 Karayiannis et al. , 1988 Krawczynskietal. 1981; Mathiesen etal. 1978 Mathiesen etal. ,1980 Figure 1 Typical course of hepatitis A in nonhuman primates, based in part on data from Asher et al. 1995 , Cohen et al. 1989 , and Mathiesen et al. 1978 , 1980 . In reality, the course of hepatitis A in nonhuman primates (and humans) can be quite variable. ALT, alanine aminotransferase; HAV, hepatitis A virus.
shedding of virus into the blood and bile (and intestinal tract) occurs before onset of disease, which is almost always very mild in nonhuman primates. In fact, onset of clinical disease usually signals diminished replication of the virus and first detection of the humoral immune response. Thus, most nonhuman primates (and human patients) develop IgG and IgM anti-HAV at approximately the time of onset of liver damage . Viremia may persist approximately 1 to 3 wk after onset of disease, and fecal shedding may persist for 2 to 3 wk longer, but infectiousness for contacts is usually minimal after clinical disease has peaked. Evidence of liver damage can be obtained by liver biopsy or by measuring serum levels of a variety of liver enzymes. The most useful for measuring hepatitis in humans and chimpanzees is alanine aminotransferase ; the most useful enzyme measurement for tamarins is isocitrate dehydrogenase.
Damage to liver cells is thought to result more from the host's immune response than from the direct effect of the virus on hepatocytes. Histological changes in the liver are not unique to hepatitis A but resemble those seen during the acute phase of infection with the other hepatitis viruses. Histological changes consist of focal necrosis, Kupffer cell proliferation and ballooning degeneration, and apoptosis of hepatocytes. Necrosis and mononuclear cell inflammation of the periportal tract are seen more frequently in hepatitis A than in hepatitis B. Heavy infiltration of inflammatory cells, principally lymphocytes but also neutrophils, eosinophils, and plasma cells, is observed. Bile retention resulting from disruption of bile canniculi follows liver cell enlargement and/or necrosis. The severity of acute hepatitis A in nonhuman primates may range from mild, with focal necrosis, to moderate, with necrosis bridging portal tracts or joining portal areas and central veins. More severe hepatitis is rarely seen but does occur in humans. Nonhuman primates are almost never symptomatic during experimental HAV infection, and all recover completely.
Applications
An important tool for evaluation of HAV infections in nonhuman primates was provided by the development of practical methods for transfecting them with RNA transcripts of full-length cDNA clones of HAV strains. The development of infectious cDNA clones of viruses provides a method for molecular engineering of the viral genome but requires a method for "transfecting" RNA transcripts of the cDNA into a living system. For strains of virus adapted to growth in cell culture, this method is relatively simple to achieve (Cohen et al. 1987) . However, for wild-type viruses and other viruses that do not replicate in cell culture, transfection must be achieved in vivo. Initially, this method required laparotomy and direct inoculation of the cDNA or its RNA transcripts directly into the liver (Emerson et al. 1992 origin, adapts the virus to more efficient replication in such cultures and usually results simultaneously in attenuation of infection for primates, including humans (Provost et al. 1988; Sjogren et al. 1992 ). Candidate live attenuated hepatitis A vaccines have been developed in this manner. Such attenuation may be explained in some (but not all) cases on the basis of diminished levels of intrahepatic replication of the virus (Karron et al. 1988 ). Attenuation of hepatitis A in chimpanzees and 5. mystax and 5. labiatus tamarins parallels attenuation observed in human volunteers, making these nonhuman primate species useful in the preclinical testing of live attenuated hepatitis A vaccine candidates.
Cross-challenge studies in tamarins (Deinhardt et al. 1975 ) and owl monkeys ) initially suggested there was a single serotype of HAV. This conclusion was confirmed by the demonstration that infection of a chimpanzee with a highly divergent simian strain of HAV conferred protection against subsequent challenge with a virulent human strain (Emerson et al. 1996) .
Transmission of HAV to chimpanzees and tamarins has provided important information about the safety and efficacy of candidate hepatitis A vaccines. After safety and efficacy trials in nonhuman primates and subsequent confirmation from clinical trials in humans, four hepatitis A vaccines have been licensed internationally (AVAXIM, Aventis Pasteur Limited, Lyon, France; EPAXAL BERNA, Swiss Serum and Vaccine Institute, Berne, Switzerland; HAVRIX, SmithKline Beecham, Rixensart, Belgium; VAQTA, Merck and Co., West Point, Pennsylvania). All of these vaccines are inactivated and consist of HAV grown in cell culture, inactivated with formalin, and combined with an appropriate adjuvant. Candidate live attenuated hepatitis A vaccines have also been developed and tested in nonhuman primates and humans but only one has been licensed: in China, where it is marketed (Mao et al. 1989 ).
Animal Models of Hepatitis E
Historical Perspective: Nonhuman Primates
Because of the extraordinary restriction of host range that is characteristic of the human hepatitis viruses, it was assumed that HEV probably would replicate only in primates. Initially, several species of primates, including humans, were examined for susceptibility to infection with HEV. Because there were no serological tests for detecting HEV or antibody to HEV (anti-HEV 1 ) at the time, the disease was simply a clinical and epidemiological entity, and it was not possible to identify with certainty the clinical materials that were infectious and therefore useful for attempting transmission to animals. The first breakthrough in understanding ENANB was Balayan's experimental transmission of the disease to himself and subsequently to cynomolgus monkeys . Later attempts to transmit the virus to cynomolgus and rhesus macaques and to 5. mystax tamarins and chimpanzees resulted in mixed success: Macaques developed evidence of infection (development of antibody [in most cases], hepatitis [usually] , and excretion of virus-like particles in the feces [occasionally] ), but attempts to demonstrate the susceptibility of chimpanzees and tamarins yielded conflicting results in different laboratories Kane et al. 1984; Poleshchuk et al. 1990; Tsarev et al. 1993 ). Eventually a number of different species of nonhuman primates were successfully infected (see below).
In the 1990s, Balayan's group extended their original observations of transmission to humans and cynomolgus monkeys to include pigs, lambs, and rats Karetnyi et al. 1993; Usmanov et al. 1991 Usmanov et al. , 1994a . These seminal studies, which were carried out in what was then the Soviet Union, initially could not be confirmed elsewhere; however, in 1997, a previously unrecognized strain of HEV was recovered from commercial swine in the United States . Infection of swine with HEV or HEV-like agents was found to be common in industrialized as well as developing countries worldwide Hsieh et al. 1999; Meng et al. 1997 Meng et al. , 1999 Wu et al. 2000) .
In 1996, confirmation of experimental transmission of HEV to laboratory rats in Thailand was reported . Then in 1999, a high prevalence of antibody to HEV was detected in wild rats at three sites in the United States and was confirmed in a number of additional sites 6 mo later Kabrane-Lazizi et al. 1999a ). The range of species of animals and birds that appear to harbor HEV or HEV-like agents continues to expand (see below), suggesting that a heterogeneous group of HEVrelated agents is ubiquitous in many species and in many regions.
Naturally Occurring Infections
In contrast to the situation with hepatitis A virus, in which sensitive and specific serological tests suitable for seroepidemiological studies were developed early and made commercially available worldwide, test development for antibody to HEV resulted in assays that were suitable for diagnosis but too insensitive for obtaining meaningful seroepidemiological data. This situation applied particularly to the two most widely used commercial tests (Genelabs, Redwood City, California; Abbott Laboratories, Delkenheim, Germany), which yielded disparate results, were not uniformly available worldwide, and were not very sensitive for detecting antibodies to genetically diverse strains of HEV. Although sensitive and specific tests suitable for seroepidemiology have been developed, they are not available commercially. Consequently, it is difficult to evaluate data collected by different laboratories with different assays. For example, the age-specific prevalence of HEV in humans as reported in the literature varies widely from study to study; although this variation is partly due to differences in the ecology of HEV infection, it is also a reflection of test variability.
In general, the most reliable serology has been performed with enzyme-linked immunosorbent assays comprising recombinant HEV capsid protein expressed in insect cells or Escherichia coli (reviewed in Purcell 2000) . Proteins representing less than the full-length capsid protein but substantially more than small epitope-containing peptides have yielded results that are confirmable from laboratory to laboratory and that are not influenced appreciably by variations in the serological and genetic makeup of HEV strains. The prevalence of antibody to HEV in a variety of animal and avian species is summarized in Table 5 . Chimpanzees, at least from one major breeding facility, were not exposed to HEV (Purcell and Emerson, unpublished data) . In contrast, both wild-caught and domestically raised macaques had serological evidence of prior exposure to HEV (Arankalle et al. 1994; Purcell, unpublished data; Purcell and Emerson, unpublished data; Tsareva et al. 1997) . Evidence existed especially for rhesus monkeys. More than one third of monkeys caught wild in India and half or more of monkeys raised domestically in open colonies in two breeding facilities in the United States had been infected with HEV or an HEVlike agent, whereas there was no evidence of exposure in isolated research colonies of rhesus monkeys at the same two facilities (Purcell, unpublished data; Purcell and Emerson, unpublished data; Tsareva et al. 1997) . As with humans, the prevalence of anti-HEV in rhesus monkeys was age related: Most animals with anti-HEV were older than 1 yr. Wildcaught and domestically raised cynomolgus monkeys also were found to have been exposed to an HEV-like agent before the time they were first bled Purcell and Emerson, unpublished data; Tsarev et al. 1993 ). Many of the macaques raised in open communities in one facility also had serological evidence of exposure to an HAVlike agent (Table 6) .
Thus, at least two enterically transmitted hepatitis viruses were endemic in the facility. Other macaque species also had serological evidence of prior HEV infection, but they appeared to be less susceptible (or less exposed) to infection than rhesus or cynomolgus monkeys (Table 5) . That naturally occurring anti-HEV in macaques was indicative of actual infection with an HEV-like agent was confirmed by demonstrating that the presence of anti-HEV correlated with protection from experimental challenge with virulent HEV Tsarev et al. 1995) .
Numerous nonprimate species have serological evidence of prior infection with HEV (Table 5 ). In particular, a very large proportion of swine, whether raised in developing or industrialized countries, had such antibody, and one study reported antibody in the sera of wild pigs in Australia . In contrast, carefully controlled herds of pigs raised for research purposes were devoid of anti-HEV in four of seven cases Meng et al. 1997; Purcell, unpublished data) . As with rhesus monkeys, the acquisition of anti-HEV was age dependent, and most pigs acquired the antibody before 4 mo of age ). An early report from the former USSR of anti-HEV in rats prompted seroepidemiological studies in the United States. A large proportion of several species of rat were found to be positive for anti-HEV Kabrane-Lazizi et al. 1999a) . As with rhesus monkeys and swine, the prevalence of anti-HEV in rats increased with age. As with HEV in swine, HEV naturally infecting rats may represent a unique virus that is well adapted to replicate in this host. Various species of mice have also been positive for anti-HEV, but generally with a lower prevalence of antibody than that found in rats (Table 5) . Finally, antibody to HEV has been detected in the sera of a few other species, including cattle, dogs, sheep, goats, and chickens. The last is particularly interesting inasmuch as an agent causing "big liver and spleen disease" of chickens has recently been shown to be genetically related to HEV (Crerar and Cross 1994; Payne et al. 1999) .
Host Range
As with hepatitis A virus, direct attempts at transmission of HEV have helped to define the host range of this virus (Table 7) . Among nonhuman primates, cynomolgus and rhesus monkeys have been consistently susceptible to infection with HEV strains obtained worldwide. Less consistent has been the response of tamarins and chimpanzees: HEV strains have been serially passaged in tamarins (5. mystax) in one laboratory ), but in others, the animals have been either refractory to infection or sparingly susceptible Tsarev etal. 1993 ). The same laboratory that was successful in infecting tamarins was unsuccessful in infecting chimpanzees (at least initially) whereas other laboratories reported typical hepatitis E in experimentally infected chimpanzees . The reasons for these discrepant results are unknown but probably relate to biological differences among different strains of HEV. Other nonhuman primates that have been infected with HEV are pig-tailed macaques, vervets, owl monkeys, squirrel monkeys, and possibly patas monkeys. Clearly, the most useful nonhuman primates for studies of hepatitis E have been cynomolgus and rhesus monkeys. Almost as useful have been chimpanzees and owl monkeys.
Nonprimate species have also been studied for susceptibility to experimental infection with HEV strains. In the early 1980s, Balayan's group reported the transmission of human HEV strains to piglets, lambs, and rats Karetnyi et al. 1993; Usmanov 1994a) . Confirmation of the susceptibility of pigs has been forthcoming, but principally with HEV strains recovered from swine. Thus, swinederived HEV was transmitted to specific pathogen-free (SPF) pigs (Halbur et al. 2001; Meng et al. 1998b ). The resulting infection was not associated with significant hepatitis, but the virus could be recovered from the animals and they developed specific anti-HEV responses. In contrast, human strains of HEV recovered from Pakistan or Mexico could not be transmitted to pigs, even though the titer of HEV in these inocula was as high as 10 5 monkey infectious doses (Meng et al. 1998a; Platt et al. 1998) . In subsequent studies, a human These animals are included in Tables 1 and 5 . 5,9,14,28 ? 1,7,25,28 ? 25 3-4+ 2,3,4,11,12,13,16,17, 24,28,29,31,33,37,38 3-4+ 1,7,8,9,18,26,27, 28,30,32,33 ? 28 ? 27,28 ? 28 ? 7,9,14,23,28 3-4 6,20,21,22,35,36 2-3+ 34 ? 15,19 3+* 10,13
3+
Modified from Vitral et al. 1998 . Some scores represent ranges of discrepant results from different laboratories. 0: not susceptible. 4+: highly susceptible *Big liver and spleen disease agent (believed to be related to HEV).
HEV isolate from the United States that was genetically closely related to swine HEV was transmitted to pigs, and, conversely, swine HEV was transmitted to rhesus monkeys and a chimpanzee (Halbur et al. 2001; Meng et al. 1998b; Purcell and Emerson, unpublished data) . Thus, closely related swine and human strains of HEV recovered in the United States reciprocally crossed species barriers and raised the specter of potential zoonotic spread of HEV. Also, because swine are candidate organ donors for xenotransplantation, the potential for transmission of HEV to immunosuppressed human organ recipients has become a concern. However, pigs experimentally infected with swine HEV or the closely related US human isolate displayed minimal pathology: The swine virus was almost entirely attenuated for swine (as it was for rhesus monkeys and a chimpanzee) whereas the US strain was slightly more virulent in swine and rhesus monkeys but less virulent than most other human strains that have been characterized in nonhuman primates (Halbur et al. 2001; Meng et al. 1988a,b) . Thus, the US human and swine isolates appear to be naturally attenuated strains of HEV.
Transmission of HEV to rats has also been confirmed, but only in regions where HEV is endemic in the human population . HEV reportedly was recovered from two rats in Nepal; the recovered HEV sequence (not disclosed) was said to be most closely related to HEV strains recovered from humans in Nepal ). Attempts to recover HEV strains from rats in the United States or to transmit HEV from wild rats trapped in the United States to laboratory rats have been unsuccessful to date (Purcell and Emerson, unpublished data) . Because such a large proportion of US rats have antibody to HEV, it is important to characterize the agent that appears to be circulating in these animals and to determine whether it is involved in zoonotic transmission to humans.
Finally, although direct attempts to transmit HEV to chickens have not been reported, the discovery that a transmissible agent of chickens, the "big liver and spleen disease virus," is genetically related to HEV makes the chicken an interesting candidate host for additional studies (Crerar and Cross 1994; Payne et al. 1999) . The agent can be transmitted intravenously and orally to chickens and intravenously to chick embryos in ovo. The virus has been recovered from liver tissue and partially sequenced.
Course of HEV Infection in Animal Models
Two macaque species, cynomolgus monkeys and rhesus monkeys, have been the most widely used species for the propagation and study of HEV, and such studies have been the most rewarding for the characterization of hepatitis E. Chimpanzees and owl monkeys have also yielded important information. Based on data obtained from these species, as well as from limited volunteer studies, a better understanding of the pathogenesis and natural history of hepatitis E in primates is emerging (Figure 2 ) (Purcell and Emerson 1999, 2000) . Exposure to HEV is thought to occur usually via the oral route, but the virus can be transmitted parenterally, at least under experimental conditions. Infection of nonhuman primates via the oral route has been successful in some (but not all) studies. In one study in which quantitative data were available, the infectivity titer of HEV as measured by intravenous inoculation was at least 10,000-fold higher than when administered orally . After exposure, (regardless of route) the first evidence of infection with HEV is found in the liver (Figure 2 ). Shortly thereafter, virus is detected in the blood, bile and feces. A site of replication in the intestinal tract has not been identified but is thought to exist. Nevertheless, most virus detected in the intestinal tract is probably there by way of bile from the liver (Kawai et al. 1999) . As with hepatitis A, peak shedding of virus into the blood and bile occurs before onset of clinical disease. Also as with hepatitis A, onset of clinical disease usually coincides with first detection of the humoral immune response, diminished replication of the virus, and beginning resolution of the infection. Both IgG and IgM class anti-HEV can usually be detected by the time liver enzymes become elevated and hepatic pathology becomes detectable. The incubation period to such hepatitis is generally longer than for hepatitis A (Figures 1 and 2) .
As with hepatitis A, damage to liver cells is thought to result more from the host's immune response than from the direct effect of the virus on hepatocytes. The histological changes in the liver of nonhuman primates, and patients, are somewhat characteristic. Histological changes include focal necrosis with minimal infiltration. Lesions can be found in all zones of the lobule. Inflammation, if present, consists of Kupffer cells and polymorphonuclear leukocytes in focal lesions that resemble drug-associated toxic hepatitis. Cholestatic hepatitis (ballooning hepatocytes, cytoplasmic cholestasis, and focal cytolytic necrosis) is common, and "pseudoglandular" modification of the hepatocyte plates has been reported in some epidemics (Ramalingaswami and Purcell 1988) . Although the mortality of hepatitis E in pregnancy, especially the third trimester of pregnancy, is reported to be as high as 20% ), attempts to reproduce this in pregnant rhesus monkeys generally have been unsuccessful Tsarev et al. 1995) . Hepatitis E never progresses to chronicity. However, recurrent (bimodal) hepatitis E has been reported in experimentally infected nonhuman primates but not humans (Poleshchuk et al. 1990) .
In experimental infections of nonhuman primates, the clinical presentation of hepatitis E is dose dependent (Tsarev etal. 1994b ). Thus, the severity of infection is directly related to the infectivity titer of challenge virus, and consistent demonstration of hepatitis in experimentally infected nonhuman primates has required challenge doses at least 1000 times greater than the minimum dose needed for infection . It is not known whether such a clinicalto-infectious dose relation exists for naturally infected Tsarev et al. 1995 . In reality, the course of hepatitis E in nonhuman primates (and humans) can be quite variable. ALT, alanine aminotransferase; HEV, hepatitis E virus.
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humans, but cycles of inapparent infection resulting from exposure to low doses of virus could explain how HEV can be maintained in a population with little or no clinical disease.
Applications
Until recently, attempts to produce an infectious cDNA clone of HEV were unsuccessful. However, transfection of cell cultures with a cDNA clone of HEV and infection of a rhesus monkey with supernatant fluids from the transfected cells were recently reported (Panda et al. 2000) . Confirmation of these results is awaited inasmuch as the RNA transcripts of the cDNA were not capped whereas genomic RNA of HEV is capped (Kabrane-Lazizi et al. 1999b ). Nonhuman primates have been very useful in determining the number of serotypes of HEV (and therefore the number of individual vaccines necessary to control hepatitis E). This determination has been achieved by cross-challenge experiments with wild-type virus , by passive immunoprophylaxis studies with viruses obtained from different regions (Pillot et al. 1995) , and by challenge of vaccinated nonhuman primates with genetically diverse HEV strains (Fuerst et al. 1996; . Fortunately, only one serotype of HEV has been identified, and therefore only one vaccine appears to be necessary for the control of hepatitis E worldwide.
The modeling of hepatitis E in nonhuman primates has provided a method for evaluating candidate hepatitis E vaccines. Recombinant candidate vaccines expressed from the second open reading frame (encoding the capsid protein) of HEV in E. coli or insect cells have been evaluated in cynomolgus and/or rhesus monkeys (Fuerst et al. 1996; Purdy et al. 1993; Tsarev et al. 1994a . One such vaccine successfully completed preclinical testing in rhesus monkeys and phase I and phase II clinical testing in volunteers and is scheduled for phase II/III field trials in Nepal (Purcell 2000) . Thus, the availability of animal models of hepatitis E has permitted the rapid development of a vaccine against this important human pathogen.
